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Background: The density of presynaptic markers of synaptic communication and plasticity, especially
synaptophysin (SYP), is significantly correlated with cognitive decline and the progression of Alzheimer’s disease
(AD), indicating that synaptic protection is an important therapeutic strategy for AD. This study aims to investigate
the synaptic protective effects of a combination of several active components extracted from the Chinese herbs
ginseng, epimedium, polygala and tuber curcumae (GEPT), in the brains of APPV717I transgenic mice.
Methods: Three-month-old APPV717I mice were arbitrarily divided into 10 groups (n = 12 per group): APP groups
receiving vehicle treatment for four or eight months (model groups), three dose groups of GEPT-treated mice for
each treatment period, and donepezil-treated mice for each treatment period. Three-month-old C57BL/6 J mice
(n = 12) were also given vehicle for four or eight months (control groups). Vehicle, donepezil or GEPT were
intragastrically administered. Immunohistochemistry (IHC) and Western blot analysis were used to assess protein
expression in the hippocampal CA1 region and ratios of SYP to β-actin levels in hippocampal tissue
homogenate, respectively.
Results: Both IHC and Western blot revealed a decrease in SYP levels in the CA1 region of 7- and 11-month-old
APPV717I transgenic mice compared with the control groups, whereas SYP levels were increased in donepezil- and
GEPT-treated transgenic mice compared with the APP group. There was a significant difference in the levels of SYP
detected by IHC between the GEPT high-dose group and the APP group after 4 months of treatment, and there
were significant differences between all three GEPT groups and the APP group after 8 months of treatment.
Western blotting showed that the SYP protein–β-actin ratio was decreased in APP mice, while donepezil- and
GEPT-treated transgenic mice showed increased trends in the SYP protein–β-actin ratios.
Conclusion: GEPT increases SYP expression and protects synapses before and after the formation of amyloid
plaques in the brains of APPV717I transgenic mice.Background
Alzheimer’s disease (AD), the most common cause of
dementia in the elderly, currently affects about 26 mil-
lion patients worldwide [1]. It is characterized clinically
by a progressive impairment of cognitive functions, such
as learning and memory, and pathologically by the accu-
mulation of β-amyloid peptides (Aβ), neurofibrillary* Correspondence: jztian@hotmail.com
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reproduction in any medium, provided the ortangles (NFTs) and neuronal degeneration [2]. Although
Aβ accumulation in neurons plays an important role in
AD pathogenesis [3,4], changes in the density of pre-
synaptic markers, specifically synaptophysin (SYP), were
suggested to be better correlated with disease progres-
sion and cognitive decline [5-9]. Moreover, evidence
from transgenic mouse models with abundant Aβ depos-
ition shows that deficits in synaptic communication and
plasticity are crucial to the development of the disease.
These synaptic changes usually occur before Aβ. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nonfibrillary species of Aβ [10-12].
Previous studies have shown that a combination of
herbal extracts called GEPT—consisting of extracts from
ginseng, epimedium, polygala, and tuber curcumae
[13]—can markedly enhance learning and memory in an
AD rat model [14]. GEPT can also reduce the level of
Aβ in APPV717I transgenic mice by inhibiting γ-
secretase (or presenilin-1 (PS1)) and promoting insulin-
degrading enzyme (IDE) and neprilysin (NEP) [13]. A
24-week Phase II clinical study [15] showed that GEPT
significantly improved the cognitive function of patients
with early-stage AD.
Synapses are considered to be the earliest site of AD
pathology, and the rate of synaptic loss is directly related
to the progression of the disease [16,17]. The pattern of
synaptic protein-specific reductions throughout the
brain reveals that synaptic loss is most commonly seen
in the hippocampus, compared with other brain regions
[18]. Among well studied synaptic proteins in dementia,
SYP is the most abundant integral synaptic vesicle pro-
tein; its levels are often measured in attempts to quantify
synapses [19]. Also, SYP is suggested to be involved
in regulating assembly of soluble N-ethylmaleimide-
sensitive fusion protein (NSF) attachment protein recep-
tors (SNAREs), vesicle fusion, endocytosis and vesicle
recycling [20-22]. SYP immunoreactivity has been
reported to be absent from neurons containing the oli-
gomeric form of Aβ, but it detected on those contain-
ing the fibrillar or monomeric forms of Aβ [23].
Neither cholinesterase inhibitors (e.g. donepezil) nor
N-methyl-D-aspartate receptor antagonists (e.g. meman-
tine), which are currently used to treated AD, are
disease-modifying treatments that stop or slow disease
progression [24]. Although there is evidence supporting
the use of single herbs or herbal formulations to comple-
ment approved medicines, current evidence supporting
their use alone is inconclusive [24]. Therefore, this study
aims to investigate the potential effects of combination
of herbs in treating AD.
Materials and methods
Preparation of drugs
GEPT (called GETO in our previous publications), con-
sists of 35% ginsenoside extracted from ginseng, 35% fla-
vonoid glycoside extracted from epimedium, 15%
tenuifolin extracted from polygala, and 15% curcumin
from tuber curcumae. GEPT was provided by Henan
Wanxi Pharmaceutical Company Limited (batch no.
20010923, China). Hydrochloric acid donepezil tablets
were provided by Eisai Pharmaceutical Company Lim-
ited (batch no. 090508A, China). GEPT was dissolved in
0.5% carboxymethyl cellulose (CMC) (Sigma, USA) at a
concentration of 30 mg/mL, and donepezil tablets werecrushed and dissolved in 0.5% CMC at a concentration
of 0.092 mg/mL.
Animals and medicine administration
Three-month-old APPV717I mice and C57BL/6 J mice
(non-transgenic inbred mice, used as vehicle controls)
were purchased from the Institute of Experimental Ani-
mals, Chinese Academy of Medical Sciences & Peking
Union Medical College (Beijing, China). The APP/
V717I transgenic mice had a C57BL/6 J genetic back-
ground and carried mutated human APP-CT100 con-
taining the London mutation, V717I, which results in
increased generation of Aβ42 and AD-like pathological
changes [25]. All animals were housed in the Pharma-
cological Experiment Center of Dongzhimen Hospital,
Beijing University of Chinese Medicine, Beijing, China.
They were maintained in a temperature-controlled (24°C)
pathogen-free vivarium, on a 12:12-h light:dark cycle (12-h
light [06:00 to 18:00], 12-h dark [18:00 to 06:00]) with free
access to food and water. All experimental procedures were
performed in compliance with the Provision and General
Recommendations of the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and
were approved by the Animal Research Ethics Board of
Beijing University of Chinese Medicine.
APPV717I transgenic mice were arbitrarily divided
into 10 groups (n = 12 per group) and received intragas-
trically administrated vehicle or medicines. APP groups
were given 0.5% CMC and donepezil groups were given
donepezil (APP +D; 0.92 mg/kg/d) for 4 or 8 months.
GEPT was administered at three dosage levels, with a
separate group for each: low dose (APP+Gl; 0.075 g/kg/d),
medium dose (APP+Gm; 0.15 g/kg/d), and high dose
(APP+Gh; 0.30 g/kg/d), also for 4 or 8 months. Male
C57BL/6 J mice served as vehicle controls (n=12) and
were given 0.5% CMC for 4 or 8 months.
Behavioral assessments
Spatial learning and memory were assessed in orienta-
tion navigation tests using the Morris water maze
(MWM) as described previously [13]. After 4 or
8 months of treatment, all mice underwent testing in the
MWM, which consisted of two days of learning and
memory training, followed by three days of probe trials.
The animals’ swim paths and the numbers of annulus
crossings were recorded on videotape; the percentage of
time spent in each quadrant and the average swim speed
were determined from these videotapes.
Tissue preparation
All behaviorally tested mice were deeply anesthetized
with 10% chloral hydrate (Loogene Biotechnology Co.,
Ltd, China) (40 mg/kg, i.p.) and pericardially perfused
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brain. Brains were immersion-fixed in 4% paraformalde-
hyde (Sun Biomedical Technology Co., Ltd, China) over-
night at 4°C and then processed in a phosphate-buffered
saline (PBS) solution containing 30% sucrose. Seven days
later, brains were embedded in paraffin. Serial coronal
sections of the hippocampus were cut at 35-μm intervals
for immunohistochemistry (IHC) staining. The brains of
three arbitrarily selected mice were separated according
to regions and snap frozen for Western blot.
IHC staining
Brain sections were deparaffinized and rehydrated in dis-
tilled water. Antigens were then unmasked in 0.01 M
citrate buffer (Sun Biomedical Technology Co., Ltd,
China) by microwave, and endogenous peroxidase activ-
ity was quenched by 0.3% hydrogen peroxide (Sun Bio-
medical Technology Co., Ltd, China) in methanol
(Sinopharm Chemical Reagent Co., Ltd, China) for
20 min at room temperature. The sections were then
blocked with 3% bovine serum albumin (Sigma-Aldrich
Co. LLC, USA) in PBS for 30 min at 37°C. After excess
serum was removed, sections were incubated with pri-
mary antibody against SYP (1:400; ab23754, Abcam,
USA) in humidified boxes at 4°C overnight. They were
then washed again and incubated with biotin-conjugated
secondary antibodies (1:300, Fuzhou Maixin Ltd, China)
for 30 min at 37°C, then washed again and incu-
bated with Streptavidin-Biotin Complex (SABC) (Wuhan
Boster Bioengineering Co., Ltd, China) for 1 h at 37°C.
Sections were subsequently developed using the chromo-
gen 3’,3-diaminobenzidine tetrachloride (DAB), after which
they were dehydrated and coverslipped. All brain sections
chosen for staining were on a similar sagittal plane and
contained approximately the same area of hippocampus.
SYP average optical density (AOD) was measured in
immunostained sections, following the instructions of the
Image Pro Plus 6.0 software (Media CY Company, USA).
“Nonspecific” IHC staining in sections was chosen as the
control area for comparison with the SYP-immunopositive
area in the neurons of the dentate gyrus.
Western blot
Western blots were performed based on a previously
described method [13]. Briefly, snap-frozen brain tissues
from hippocampus and cortex were weighed and homo-
genized in brain tissue lysis buffer (Loogene Biotechnol-
ogy Co., Ltd, China) using a small pestle on ice, at a
ratio of 1:10 (w/v) for 2 min, and incubated on ice for
30 min. Homogenates were centrifuged at 4300 x g at
4°C for 30 min, and supernatants were collected. The
level of protein in the supernatants was determined bythe modified Bradford method [26] using Coomassie
Brilliant Blue G-250 (Nanjing Jiancheng Bioengineering
Institute, China). Loading buffer was added to samples
at a ratio of 4:1, after which samples were placed in boil-
ing water for 5 min and then immediately chilled on ice.
Aliquots (10 μL) of each sample and 5 μL of marker
(10–170 kDa) were loaded onto 10% acrylamide gels
(Sigma-Aldrich Co. LLC, USA) and subjected to SDS-
PAGE using the Bio-Rad mini gel system (Bio-Rad,
USA). Proteins were then electro-blotted onto polyviny-
lidine difluoride membranes. Membranes were blocked
with 5% milk at 4°C overnight, and then incubated with
primary antibody (anti-SYP antibody, ab23754, 1:5000).
After three washes with PBS containing 0.5% Tween 20
(PBST) (Sun Biomedical Technology Co., Ltd, China),
membranes were incubated at room temperature for 1 h
with anti-rabbit IgG (H&L) (Equitech Bio, Inc. USA)
horseradish peroxidase-conjugated secondary antibody
(Promega Co., USA) at 1:10,000 on a shaker. After three
washes with PBST, blots were developed using Luminol
reagent (Pierce Biotechnology, USA). Densitometric ana-
lysis of the blots was completed using Phoretix 1D soft-
ware (Total Lab Ltd, UK). Expression of SYP protein is
shown as the SYP protein-β actin ratio.Statistical analysis
All data were analyzed using SPSS 13.0 software (IBM
Software, USA) and are presented as mean± standard de-
viation (SD). One-way ANOVA with Tukey’s post-hoc test
was used when comparisons were made between two
groups. P< 0.05 was considered statistically significant.Results
Spatial learning and memory abilities
During the 5-day spatial learning and memory test,
training was done for the first two days and testing was
done on the following three days. The average escape la-
tencies of 7-month-old mice were all gradually decreased
during the three day test. However, the average escape
latencies in 7-month-old APPV717I transgenic mice
(44.87 ± 11.98 s) were significantly longer than those in
vehicle control mice of the same age (27.53 ± 14.21 s)
(P= 0.006) on the fifth training day. The mice in treated
APP groups showed decreased escape latencies in a
two-minute test on the fifth training day. Of these,
APP+D mice had the shortest escape latencies
30.58 ± 15.42 s (P= 0.047), followed by APP+Gh mice
with a latency of (30.91 ± 13.01 s) (P= 0.036), APP +Gm
mice with a latency of 31.42 ± 14.80 s (P= 0.049), and
APP+Gl mice with a latency of 35.00 ± 15.75 s
(P= 0.008). Similar results were found in 11-month-old
mice (Tables 1 and 2).
Table 1 Escape latencies of 7-month-old mice
Group Day 3 Day 4 Day 5
Control 36.80 ± 12.60 32.87 ± 15.5 27.53 ± 14.21
APP 50.33 ± 9.39▲▲ 47.73 ± 8.65▲▲ 44.87 ± 11.98▲▲
APP+D 38.25 ± 14.41● 34.42 ± 12.84● 30.58 ± 15.42●
APP+Gl 40.93 ± 14.11 36.93 ± 13.78● 35.00 ± 15.75
APP+Gm 42.92 ± 13.05 38.58 ± 14.15 31.42 ± 14.80●
APP+Gh 38.45 ± 14.12● 35.27 ± 14.01● 30.91 ± 13.01●
The effects of GEPT on escape latency in 7-month-old mice (n = 12) were
assessed in orientation navigation tests using the Morris Water Maze (MWM).
Data are expressed as mean ± standard deviation (SD). Control: C57BL/6 J
mice; APP: APPV717I mice; APP+D: APP mice treated with donepezil;
APP+Gl: APP mice treated with GEPT (low dose); APP+Gm: APP mice treated
with GEPT (medium dose); APP+Gh: APP mice treated with GEPT (high dose).
●P< 0.05 vs. APP mice alone; ▲▲P< 0.01 vs. control mice, one-way ANOVA.
Table 3 Expression of SYP in the hippocampal CA1 region
in 7- and 11-month-old mice
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IHC staining
IHC analysis showed a significant decrease in SYP ex-
pression through the measurement of AOD in the CA1
region of 7-month-old APPV717I transgenic mice
(P= 0.002 compared with controls), while SYP expres-
sion was increased in donepezil- and GEPT-treated
groups (Table 3). There was only a significant difference
between the APP-Gh group and the non-treated APP
group (P= 0.031). Similar results were obtained for SYP
expression in the CA1 region of 11-month-old experi-
mental mice, but at that age, there were also significant
differences between the APP-Gm group and the APP
group (P= 0.019), and between the APP-Gl group and
the APP group (P= 0.032) (Table 3). There was no sig-
nificant difference between the donepezil-treated group
and the APP group in either 7- or 11-month-old experi-
mental mice (Figures 1 and 2).
Western blot
In 7-month-old experimental mice, Western blot ana-
lysis revealed a decrease in the ratio of SYP protein to β-
actin (internal control) in the hippocampus of APP mice
when compared to control mice, but there was noTable 2 Escape latencies of 11-month-old mice
Group Day 3 Day 4 Day 5
Control 39.17 ± 12.68 36.75 ± 14.72 33.08 ± 14.49
APP 51.33 ± 7.80▲ 49.83 ± 7.78▲ 47.17 ± 10.19▲
APP+D 42.25 ± 14.23 40.00 ± 12.69 34.83 ± 13.60●
APP+Gl 43.27 ± 10.32 37.64 ± 13.52● 37.55 ± 13.92
APP+Gm 41.60 ± 10.51 43.60 ± 11.61 35.50 ± 13.91●
APP+Gh 40.00 ± 12.34● 38.83 ± 14.45● 34.42 ± 12.38●
The effects of GEPT on the escape latency in 7-month-old mice (n = 12) were
assessed in orientation navigation tests using the Morris Water Maze (MWM).
Data are expressed as mean ± standard deviation (SD). Control: C57BL/6 J
mice; APP: APPV717I mice; APP+D: APP mice treated with donepezil;
APP+Gl: APP mice treated with GEPT (low dose); APP+Gm: APP mice treated
with GEPT (medium dose); APP+Gh: APP mice treated with GEPT (high dose).
●P< 0.05 vs. APP mice alone; ▲P< 0.05 vs. control mice, one-way ANOVA.significant difference. However, SYP expression was
increased in all donepezil- or GEPT-treated transgenic
mice when compare to APP mice, and there was a
significant difference in the levels of SYP between the
APP-Gh group and the APP group (P= 0.041). Similar
results were obtained for SYP expression in the hippo-
campus of 11-month-old experimental mice, while there
was no significant difference between each group
(Figure 3).
Discussion
Although synaptic decline has been clearly shown to be
related to the duration and severity of dementia in the
AD process [8,16,17], and synapse loss has been shown
to be positively correlated with neurons containing NFTs
[27], the association between presynaptic proteins and
senile plaques is not clear [18]. Meanwhile, only the sol-
uble form of Aβ has been found to be a predictor of syn-
aptic change in the entorhinal cortex and superior
frontal gyrus [28]. SYP immunoreactivity has been
reported to be absent around neurons containing the oli-
gomeric form of Aβ, but it is present around those con-
taining the fibrillar or monomeric forms [23]. Therefore,
this study focused on the synaptic decline in APP/V717I
transgenic mice and the protective effects of GEPT in
7- and 11-month old transgenic mice.
In APPV717I transgenic mice, the formation of amyl-
oid plaques begins at around nine months of age [29,30],
but learning and memory deficits have been detected as
early as four months of age, and gradually become worse
during the following 12 months; after 16 months of age
the learning and memory deficits still exist, but are sig-
nificantly less severe [31]. These findings indicate the
critical involvement of amyloid peptides in defective LTP
in APP transgenic mice. The escape latency in theGroup Average optical density
7-month-old mice 11-month-old mice
Control 0.020 ± 0.002 0.026 ± 0.009
APP 0.013 ± 0.003▲▲ 0.015 ± 0.004▲
APP+D 0.017 ± 0.003 0.024 ± 0.008
APP+Gl 0.016 ± 0.003 0.027 ± 0.006●
APP+Gm 0.017 ± 0.005 0.028 ± 0.007●
APP+Gh 0.019 ± 0.005● 0.031 ± 0.011●●
The effects of GEPT extract on the expression of SYP in the hippocampal CA1
region in 7- and 11-month-old mice (n = 5 per group) were assessed by IHC
staining. Average optical densities of the SYP positive neuronal area (anti-body
for SYP, 1:400) are expressed as mean ± standard deviation (SD). Control:
C57BL/6 J mice; APP: APPV717I mice; APP +D: APP mice treated with
donepezil; APP+Gl: APP mice treated with GEPT (low dose); APP+Gm: APP
mice treated with GEPT (medium dose); APP+Gh: APP mice treated with
GEPT (high dose). ●P< 0.05 vs. APP mice alone, ●●P< 0.01 vs. APP mice;
▲▲P< 0.01 vs. control mice, one-way ANOVA.
Figure 1 Expression of SYP in the hippocampal CA1 region in 7-month-old mice. The effects of GEPT on the expression of SYP in the
hippocampal CA1 region in 7-month-old experimental mice were assessed by IHC staining. Average optical densities of the SYP positive neuronal
area (anti-body for SYP, 1:400) are expressed as mean± SD (n = 5). Control: C57BL/6 J mice; APP: APPV717I mice; APP+D: APP mice treated with
donepezil; APP+Gl: APP mice treated with GEPT (low dose); APP+Gm: APP mice treated with GEPT (medium dose); APP+Gh: APP mice
treated with GEPT (high dose). ●P< 0.05 vs. APP mice alone, ●●P< 0.01 vs. APP mice; ▲▲P< 0.01 vs. control mice, ANOVA.
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decreased in an object recognition test. To observe the
synaptic protection effects of GEPT before and after
amyloid plaque formation, 3-month-old APPV717I
transgenic mice were treated with GEPT up to the ages
of 7 and 11 months.
In previous studies, GEPT markedly enhanced learning
function and memory abilities in AD rat models and sig-
nificantly improved spatial learning and memory abilities
in APPV717I transgenic mice following 8 months and
3 months of treatment with GEPT, suggests that GEPT
could significantly prevent memory and cognitive
impairments and delay memory decline in those demen-
tia models [13,14]. The potential mechanism of GEPT
action in the brains of APPV717I transgenic mice may
be through the inhibition of PS1 activity rather than
through inhibition of Beta-secretase enzyme (BACE1)
and the promotion of IDE and NEP activity [13]. How-
ever, it is not known if GEPT has synaptic protective
effects in APPV717I mice. In the present study, both
IHC and Western blot analyses revealed a significant de-
crease in SYP levels in the CA1 region of the brains of7- and 11-month-old APPV717I transgenic mice,
whereas SYP levels were increased in donepezil- and
GEPT-treated transgenic mice. There was a significant
difference in SYP levels between the APP-Gh group and
untreated transgenic mice aged 7 months. IHC analysis
showed significant differences in SYP levels between
each of the three GEPT-treated groups and untreated
transgenic mice aged 11 months, whereas there were no
significant differences between the donepezil-treated
group and the nontreated transgenic mice group at the
same age. Western blot analysis showed that the SYP
protein–β-actin ratio was only decreased in APP mice
when compared to vehicle-treated control mice, while
the ratio was increased in donepezil- and GEPT-treated
transgenic mice; however, there was no significant differ-
ence in ratios among each group. These data indicated
that GEPT, especially at a high dose, can act as a synap-
tic protective agent in APP mice, before the formation
of amyloid plaques. The present findings were consistent
with those of a 24-week preliminary study of GEPT that
showed a significant improvement in cognitive function
in patients in the early stage of AD [15].
Figure 2 Expression of SYP in the hippocampal CA1 region in 11-month-old mice. The effects of GEPT on the expression of SYP in the
hippocampal CA1 region in 11-month-old experimental mice were assessed by IHC staining. Average optical densities of the SYP positive
neuronal area (anti-body for SYP, 1:400) are expressed as mean± SD (n = 5). Control: C57BL/6 J mice; APP: APPV717I mice; APP+D: APP mice
treated with donepezil; APP+Gl: APP mice treated with GEPT (low dose); APP+Gm: APP mice treated with GEPT (medium dose); APP+Gh: APP
mice treated with GEPT (high dose). ▲P <0.05 vs. control group, ●P< 0.05 vs. APP group, ●●P< 0.01 vs. APP group, one-way ANOVA.
Shi et al. Chinese Medicine 2012, 7:13 Page 6 of 8
http://www.cmjournal.org/content/7/1/13SYP, a well-studied synaptic protein in cases of dementia,
is the most abundant integral synaptic vesicle protein and
its levels are often measured in attempts to quantify synap-
ses [19]. The present study investigated the influence ofFigure 3 Expression of SYP proteins (SYP–β-actin ratio) in hippocamp
mice. The effects of GEPT on the expression of SYP in hippocampal tissue
determined by Western blot (anti-body for SYP, 1:5000) and subsequently a
Control: C57BL/6 J mice; APP: APPV717I mice; APP+D: APP mice treated
APP+Gm: APP mice treated with GEPT (medium dose); APP+Gh: APP mi
one-way ANOVA.GEPT on SYP expression before and after the formation of
amyloid plaques in the brains of APPV717I transgenic
mice. The results not only revealed the mechanism of ac-
tion of GEPT in providing synaptic protection, but alsoal tissue homogenates of 7- and 11-month old experimental
homogenates of 7- and 11-month old experimental mice were
nalyzed by densitometry. β-actin served as an internal control.
with donepezil; APP+Gl: APP mice treated with GEPT (low dose);
ce treated with GEPT (high dose). ●P< 0.05 vs. APP group,
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are still some outstanding issues in this study. First, SYP
levels in the brains of APPV717I transgenic mice did not
decrease between 7 and 11 months of age. This may be be-
cause a four-month period is not long enough for APP/
V717I transgenic mice to show a clear decrease in SYP ex-
pression. However, our findings clearly showed that GEPT
can time-dependently increase expression of SYP. Second,
SYP expression in the brain is only one of a number of
synaptic markers that are significantly correlated with dis-
ease progression and cognitive decline [5-9]. Therefore,
further studies in other AD transgenic mice, over a longer
time span or investigating other synaptic markers, should
be conducted.Conclusion
GEPT increases SYP expression and protects synapses
before and after the formation of amyloid plaques in the
brains of APPV717I transgenic mice.
Abbreviations
SYP: Synaptophysin; GEPT: Ginseng, epimedium, polygala and tuber curcumae;
IHC: Immunohistochemistry; Aβ: β-amyloid peptides; NFTs: Neurofibrillary
tangles; PS1: γ-secretase (or presenilin-1); IDE: Insulin-degrading enzyme;
NEP: Neprilysin; SNAREs: N-ethylmaleimide-sensitive fusion protein (NSF)
attachment protein receptors; CMC: Carboxymethyl cellulose; MWM: Morris
water maze; PBS: Phosphate-buffered saline; SABC: Streptavidin-Biotin
Complex; DAB: Chromogen 3’,3-diaminobenzidine tetrachloride;
AOD: Average optical density; PBST: PBS containing 0.5% Tween 20;
BACE1: Beta-secretase enzyme.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JT and JS designed the study, conceived, wrote and finalized the manuscript.
LY conducted the experiments. MW and XZ analyzed and prepared the
manuscript. PW conducted the Western blot and IHC experiments. YW
reviewed the design of the study and was involved in discussions of the
study. All authors read and approved the final manuscript.
Acknowledgments
The study was supported by a grant from the Innovative Research Team for
Alzheimer’s Disease’s Prevention and Treatment, Ministry of Education, P. R.
China (No. IRT-08-010); the Project on Absorption of Intellects by Institutions
of Higher Education for Academic Disciplinary Innovations (the “111 Project”)
(No. B08006); the Program for New Century Excellent Talents in University
(No. NECT-07-0117); the National Key Technology R&D Program (No.
2009BA177B09); the National Natural Science Foundation of China (No.
30973738); The Technological Platform of Clinical Evaluation and Research
for New Herbal Medicinal Products (2011ZX09302-006-01); and the
Innovative Research Team at the Beijing University of Chinese Medicine (No.
2011-CXTD-21).
Author details
1Department of Neurology, Dongzhimen Hospital, Beijing University of
Chinese Medicine, Beijing 100700, China. 2Clinical Neuroscience Research
Group, The University of Manchester, Hope Hospital, Stott Lane, Salford,
Manchester M6 8HD, UK. 3Key Laboratory of Chinese Internal Medicine
(Beijing University of Chinese Medicine), Ministry of Education, Beijing, China.
4Institute of Clinical Medicine, China Academy of Chinese Medical Sciences,
Beijing 100700, China.Received: 14 November 2011 Accepted: 18 May 2012
Published: 9 June 2012References
1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM: Forecasting the
global burden of Alzheimer’s disease. Alzheimers Dement 2007, 3:186–191.
2. Selkoe DJ: Normal and abnormal biology of the beta-amyloid precursor
protein. Annu Rev Neurosci 1994, 17:489–517.
3. Selkoe DJ: The molecular pathology of Alzheimer’s disease. Neuron 1991,
6:487–498.
4. Hardy J, Higgins G: Alzheimer’s disease: the amyloid cascade hypothesis.
Science 1992, 256:184–185.
5. Davies CA, Mann DMA, Sumpter PQ, Yates PO: A quantitative
morphometric analysis of the neuronal and synaptic content of the
frontal and temporal cortex in patients with Alzheimer’s disease. J Neurol
Sci 1987, 78:151–164.
6. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA,
Katzman R: Physical basis of cognitive alterations in alzheimer’s disease:
Synapse loss is the major correlate of cognitive impairment. Ann Neurol
1991, 30:572–580.
7. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ: Loss of the
presynaptic vesicle protein synaptophysin in hippocampus correlates
with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol
1997, 56:933–944.
8. DeKosky ST, Scheff SW: Synapse loss in frontal cortex biopsies in
Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 1990,
27:457–464.
9. Selkoe DJ: Alzheimer’s disease is a synaptic failure. Science 2002,
298:789–791.
10. Rowan MJ, Klyubin I, Cullen WK, Anwyl R: Synaptic plasticity in animal
models of early Alzheimer’s disease. Philos Trans R Soc Lond B Biol Sci
2003, 358:821–828.
11. Saganich MJ, Schroeder BE, Galvan V, Bredesen DE, Koo EH, Heinemann SF:
Deficits in synaptic transmission and learning in Amyloid Precursor
Protein (APP) transgenic mice require C-Terminal cleavage of APP. J
Neurosci 2006, 26:13428–13436.
12. Liu L, Orozco IJ, Planel E, Wen Y, Bretteville A, Krishnamurthy P, Wang L,
Herman M, Figueroa H, Yu WH, et al: A transgenic rat that develops
Alzheimer’s disease-like amyloid pathology, deficits in synaptic plasticity
and cognitive impairment. Neurobiol Dis 2008, 31:46–57.
13. Tian J, Shi J, Zhang L, Yin J, Hu Q, Xu Y, Sheng S, Wang P, Ren Y, Wang R,
Wang Y: GEPT extract reduces Abeta deposition by regulating the
balance between production and degradation of Abeta in APPV717I
transgenic mice. Curr Alzheimer Res 2009, 6:118–131.
14. Tian J, Xu Y, Sheng S, Shi J, Yin J, Wang Y: Influence of GETO extract on
myelin sheath structure and myelin basic protein content in the brain
with AD model. Alzheimers Dement 2006, 2:s601.
15. Miao Y: Part 5: a randomized, double-blind and parallel control study of
GEPT extract in the treatment of amnestic mild cognitive impairment.
PhD thesis. Beijing University of Chinese Medicine 2008:95–117.
16. Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P: Synaptic
pathology in Alzheimer’s disease: relation to severity of dementia, but
not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural
Transm 1996, 103:603–618.
17. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch
MP, Albert MS, Hyman BT, Irizarry MC: Early Abeta accumulation and
progressive synaptic loss, gliosis, and tangle formation in AD brain.
Neurology 2004, 62:925–931.
18. Honer WG: Pathology of presynaptic proteins in Alzheimer’s disease:
more than simple loss of terminals. Neurobiol Aging 2003, 24:1047–1062.
19. Clare R, King VG, Wirenfeldt M, Vinters HV: Synapse loss in dementias. J
Neurosci Res 2010, 88:2083–2090.
20. Edelmann L, Hanson PI, Chapman ER, Jahn R: Synaptobrevin binding to
synaptophysin: a potential mechanism for controlling the exocytotic
fusion machine. EMBO J 1995, 14:224–231.
21. Valtorta F, Pennuto M, Bonanomi D, Benfenati F: Synaptophysin: leading
actor or walk-on role in synaptic vesicle exocytosis? Bioessays 2004,
26:445–453.
22. Daly C, Ziff EB: Ca2+−dependent Formation of a Dynamin-
Synaptophysin Complex. J Biol Chem 2002, 277:9010–9015.
Shi et al. Chinese Medicine 2012, 7:13 Page 8 of 8
http://www.cmjournal.org/content/7/1/1323. Ishibashi K-I, Tomiyama T, Nishitsuji K, Hara M, Mori H: Absence of
synaptophysin near cortical neurons containing oligomer Aβ in
Alzheimer’s disease brain. J Neurosci Res 2006, 84:632–636.
24. Tian J, Shi J, Zhang X, Wang Y: Herbal therapy: a new pathway for the
treatment of Alzheimer’s disease. Alzheimers Res Ther 2010, 2:30.
25. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold K-H, Mistl C,
Rothacher S, Ledermann B, Bürki K, Frey P, Paganetti PA, et al: Two amyloid
precursor protein transgenic mouse models with Alzheimer disease-like
pathology. Proc Natl Acad Sci USA 1997, 94:13287–13292.
26. Bradford MM: A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Anal Biochem 1976, 72:248–254.
27. Callahan LM, Coleman PD: Neurons bearing neurofibrillary tangles are
responsible for selected synaptic deficits in Alzheimer’s disease. Neurobiol
Aging 1995, 16:311–314.
28. Lue L-F, Kuo Y-M, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH,
Rydel RE, Rogers J: Soluble amyloid [beta] peptide concentration as a
predictor of synaptic change in Alzheimer’s disease. Am J Pathol 1999,
155:853–862.
29. Dewachter I, Van Dorpe J, Smeijers L, Gilis M, Kuiperi C, Laenen I, Caluwaerts
N, Moechars D, Checler F, Vanderstichele H, Van Leuven F: Aging increased
amyloid peptide and caused amyloid plaques in brain of old APP/V717I
transgenic mice by a different mechanism than mutant presenilin1. J
Neurosci 2000, 20:6452–6458.
30. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K,
Gordon M, Tan H, Games D, et al: Amyloid precursor protein processing
and Aβ42 deposition in a transgenic mouse model of Alzheimer disease.
Proc Natl Acad Sci USA 1997, 94:1550–1555.
31. Mantle D, Pickering AT, Perry EK: Medicinal plant extracts for the
treatment of dementia: a review of their pharmacology, efficacy and
tolerability. CNS Drugs 2000, 13:201–213.
doi:10.1186/1749-8546-7-13
Cite this article as: Shi et al.: A combination extract of ginseng,
epimedium, polygala, and tuber curcumae increases synaptophysin
expression in APPV717I transgenic mice. Chinese Medicine 2012 7:13.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
